Popular Stories

Datapoint

Datapoint: FDA Approves First Interchangeable Humira Biosimilar

The FDA last week approved Boehringer Ingelheim’s Cyltezo as the first interchangeable biosimilar for AbbVie’s Humira. It is the second U.S.-approv...

read more
Datapoint: Oscar Partners With Colorado Health Systems in Statewide Expansion Effort

Startup insurer Oscar Health is partnering with three Colorado health systems as it prepares to offer individual and family plans statewide for the...

read more

Health Plan Weekly

With COVID Testing Set to Surge, Insurers Fret About Costs

While two separate administrations have now specified that health insurers must cover, without cost sharing, all COVID-19 tests used for individual...

read more
Could Payers, Plan Sponsors Pick Retail ‘Dance Partners?’

In a series of recent moves, large retailers with pharmacy operations have struck deals with or acquired smaller companies with the aim of adding o...

read more

Pulse Checks

Zitter Pulse Check: Melanoma

Coverage Melanoma is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints a...

read more
Zitter Pulse Check: Orphan Disease

Coverage Orphan disease is a high-cost category with an increasing number of therapies that treat the conditions. To help stakeholders absorb datap...

read more

RADAR on Drug Benefits

Merck COVID-19 Drug Could Gain Emergency Use Authorization

Merck & Co. has made waves by claiming one of its antiviral drugs, molnupiravir, could reduce hospitalizations for COVID-19 by roughly half — a...

read more
More MA-PD, PDP Members Will Be in 4-Star Plans in 2022

CMS, in its recent release of 2022 star ratings for private Medicare plans, reported that the percentage of members in plans rated 4 stars and abov...

read more
VIEW PREVIOUS ARTICLES

About AIS Health

AIS Health is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. AIS Health maintains journalistic independence from our parent company, MMIT. We are committed to integrity in reporting and bringing transparency to health industry data.

ais-health-logo

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today